Form 4: HilleVax Director Shelley Chu Receives Equity Grant as Part of Compensation Program

HilleVax, Inc. Director Shelley Chu was granted 17,199 Restricted Stock Units (RSUs) on June 23, 2025, as part of the company's non-employee director compensation program.

Summary

• Shelley Chu, a Director of HilleVax, Inc. (HLVX), was granted 17,199 Restricted Stock Units (RSUs).
• The grant occurred on June 23, 2025.
• The RSUs were granted at a price of $0.00, indicating they are part of a compensation package rather than a purchase.
• These RSUs will vest 100% on the earlier of the first anniversary of the grant date or a Change in Control, provided Ms. Chu continues her service on the board.
• Following this transaction, Shelley Chu beneficially owns 17,199 shares of common stock directly.

Sentiment

Score: 5

Explanation: The document reports a routine equity grant to a director as part of a standard compensation program. This is a neutral event, neither significantly positive nor negative, and is an expected part of corporate operations.

Positives

• The grant of Restricted Stock Units (RSUs) to Director Shelley Chu aligns her interests with those of shareholders, as the value of her compensation is tied to the company's stock performance.
• The RSU grant is part of a standard non-employee director compensation program, indicating a structured approach to board remuneration.

Negatives

• The issuance of 17,199 Restricted Stock Units (RSUs) represents a potential future dilution of existing shareholder equity upon vesting.

Risks

• The vesting of the RSUs is contingent on Shelley Chu's continued service on the board of directors, meaning the company retains her expertise for at least the vesting period.
• A "Change in Control" event could accelerate the vesting of these RSUs, potentially leading to earlier dilution.

Industry Context

The granting of Restricted Stock Units (RSUs) to non-employee directors is a common practice in the biotechnology and pharmaceutical industries, as well as across many publicly traded sectors. This form of compensation is designed to attract and retain qualified board members by aligning their financial interests with the long-term performance of the company's stock. It is a standard component of corporate governance and executive compensation strategies.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) to a non-employee director like Shelley Chu by HilleVax, Inc. is consistent with common compensation practices observed across the biotechnology and broader public company landscape.
• Companies such as Moderna (MRNA), BioNTech (BNTX), and Gilead Sciences (GILD) frequently utilize equity-based compensation, including RSUs, for their non-executive directors to incentivize long-term value creation and align director interests with shareholders.
• While the specific number of units (17,199) and vesting schedule (1-year anniversary or change in control) are specific to HilleVax's compensation program, the underlying mechanism of using equity for director remuneration is a widely accepted industry standard.

Corporate Governance

Related Party Transactions

• The grant of Restricted Stock Units (RSUs) to Shelley Chu, a director of HilleVax, Inc., constitutes a related party transaction as it involves compensation provided to a member of the company's board.

Stakeholder Impact

• Shareholders: Potential minor dilution upon vesting of the 17,199 RSUs, but also improved alignment of director interests with long-term stock performance.
• Employees: No direct impact mentioned, but the compensation structure for directors can reflect broader company compensation philosophies.

Next Steps

• The RSUs are expected to vest on the first anniversary of the grant date (June 23, 2026) or upon a Change in Control, subject to Shelley Chu's continued service.

Key Dates

Keywords

HilleVax, HLVX, Shelley Chu, Director, Restricted Stock Units, RSU, Equity Grant, Compensation, SEC Form 4, Insider Transaction, Corporate Governance, Biotech, Pharmaceutical